Oxford Nanopore said Norway’s MATRIX program, supported by regional health authorities and the Norwegian Cancer Society, has begun rolling out rapid nanopore sequencing for central nervous system tumor classification across the country. The rollout will integrate the assay into Norway’s National Infrastructure for Precision Diagnostics (InPreD). The program follows a Phase 1 clinical evaluation of 50 CNS tumor samples, where nanopore-based classification showed strong agreement with established diagnostic methods. Phase 2 will start at Oslo University Hospital, Haukeland University Hospital, and St. Olavs Hospital, with additional sites planned. Oxford Nanopore said it will expand the collaboration to incorporate variant detection, copy number benchmarking, single-cell transcriptomics, and genome-wide methylation as the assay workflows mature.